ArticleEJNMMI research2018
[
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Clinical Practice Guidelines forAnnals of nuclear medicine · 2025Guideline
- A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- [European journal of nuclear medicine and molecular imaging · 2020Guideline
- Utility and limitations of 18F-fluciclovine PET for biopsy targeting in a nonenhancing diffuse glioma with a gliomatosis cerebri-like growth pattern: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Article
- CD98 Light Chain LAT1 Tracers in PET-CT Diagnosis of Cancer Patients.Anti-cancer agents in medicinal chemistry · 2026Review
- A pathologically diagnosed multinodular and vacuolating neuronal tumor without typical multiple nodules: a case report.Frontiers in radiology · 2026Article
- Evaluation of a digital bismuth germanium oxide PET/CT system according to the Japanese brain tumor phantom test forPhysical and engineering sciences in medicine · 2025Article
- Study of 18 F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy.Journal of neuro-oncology · 2025Article
- Identification of small distant glioblastoma lesions using 18F-fluciclovine positron emission tomography: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Impact of [Annals of nuclear medicine · 2024Article
- Peritumoral Brain Zone in Astrocytoma: Morphology, Molecular Aspects, and Clinical Manifestations (Review).Sovremennye tekhnologii v meditsine · 2024Review
- Diagnostic accuracy of anti-3-[European journal of nuclear medicine and molecular imaging · 2024Article
- Diagnostic Accuracy of PET withDiagnostics (Basel, Switzerland) · 2023Review
- Feasibility of [European journal of nuclear medicine and molecular imaging · 2023Article
- Article
- In vitro evaluation of (S)-2-amino-3-[3-(2-EJNMMI research · 2023Article
- PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach.Frontiers in nuclear medicine · 2023Review
- Tracers progress for positron emission tomography imaging of glial-related disease.Journal of biomedical research · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe ability to accurately and non-invasively distinguish high-grade glioma from low-grade glioma remains a challenge despite advances in molecular and magnetic resonance imaging. We investigated the ability of fluciclovine (
resultsSixteen patients with a total of 18 newly diagnosed low-grade gliomas (n = 6) and high grade gliomas (n = 12) underwent fluciclovine PET imaging after histopathologic assessment. Fluciclovine PET analysis comprised tumor SUV
conclusionsFluciclovine PET produces high-contrast images between both low-grade and high grade gliomas and normal brain by visual and semiquantitative analysis. Fluciclovine PET appears to discriminate between low-grade glioma and high-grade glioma, but must be validated with a larger sample size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.